SOPHiA GENETICS (SOPH) partnered with Precision for Medicine to enhance biomarker discovery and precision medicine services, Precision for Medicine said Tuesday.
The company said it will integrate SOPHiA's DDM Platform for biomarker discovery, clinical trial assays, and advanced algorithms to expand its clinical trial capabilities.
The partnership will enable biopharma companies to accelerate clinical trial design, patient stratification, and data analysis through AI-driven algorithms that analyze complex multimodal data, including genomic, radiomic, and clinical data, the company said.
Additionally, the company said the MSK-ACCESS liquid biopsy test powered by SOPHiA DDM, supported by AstraZeneca (AZN), will be available as a service for biopharma clients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.